Wall Street brokerages forecast that Voyager Therapeutics (NASDAQ:VYGR) will post earnings of ($0.57) per share for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Voyager Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.77) and the highest estimate coming in at ($0.44). Voyager Therapeutics reported earnings of ($0.65) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 12.3%. The firm is expected to report its next earnings results on Tuesday, May 8th.
On average, analysts expect that Voyager Therapeutics will report full-year earnings of ($2.54) per share for the current year, with EPS estimates ranging from ($3.36) to ($1.20). For the next year, analysts anticipate that the company will post earnings of ($3.28) per share, with EPS estimates ranging from ($4.70) to ($2.61). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Voyager Therapeutics.
Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Wednesday, March 14th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.32. Voyager Therapeutics had a negative return on equity of 63.18% and a negative net margin of 697.03%. The business had revenue of $6.35 million for the quarter, compared to analysts’ expectations of $5.81 million.
In other news, CFO Jane Henderson sold 11,200 shares of Voyager Therapeutics stock in a transaction on Friday, March 23rd. The stock was sold at an average price of $20.52, for a total transaction of $229,824.00. Following the sale, the chief financial officer now directly owns 19,900 shares in the company, valued at approximately $408,348. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Bernard Ravina sold 2,451 shares of Voyager Therapeutics stock in a transaction on Tuesday, April 10th. The stock was sold at an average price of $18.38, for a total value of $45,049.38. The disclosure for this sale can be found here. Insiders have sold a total of 66,908 shares of company stock worth $1,574,258 over the last quarter. Company insiders own 8.00% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN raised its stake in Voyager Therapeutics by 312.8% in the 3rd quarter. Wells Fargo & Company MN now owns 377,190 shares of the company’s stock valued at $7,766,000 after acquiring an additional 285,806 shares during the period. Aevitas Wealth Management Inc. bought a new stake in Voyager Therapeutics in the 4th quarter valued at about $1,400,000. Bank of New York Mellon Corp raised its stake in Voyager Therapeutics by 16.2% in the 3rd quarter. Bank of New York Mellon Corp now owns 61,858 shares of the company’s stock valued at $1,274,000 after acquiring an additional 8,633 shares during the period. Clearbridge Investments LLC raised its stake in Voyager Therapeutics by 3,214.5% in the 4th quarter. Clearbridge Investments LLC now owns 68,046 shares of the company’s stock valued at $1,130,000 after acquiring an additional 65,993 shares during the period. Finally, Lazard Asset Management LLC bought a new stake in Voyager Therapeutics in the 4th quarter valued at about $334,000. Institutional investors own 78.22% of the company’s stock.
NASDAQ:VYGR traded down $0.23 during trading hours on Monday, hitting $18.52. 87,188 shares of the company traded hands, compared to its average volume of 431,002. Voyager Therapeutics has a one year low of $8.10 and a one year high of $31.91. The stock has a market cap of $603.88, a PE ratio of -6.96 and a beta of 2.98.
ILLEGAL ACTIVITY WARNING: “Voyager Therapeutics (VYGR) Expected to Announce Earnings of -$0.57 Per Share” was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.chaffeybreeze.com/2018/04/16/voyager-therapeutics-vygr-expected-to-announce-earnings-of-0-57-per-share.html.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.